{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:04:29Z","timestamp":1792591469436,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.seizure.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T15:44:41Z","timestamp":1742053481000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence"],"prefix":"10.1016","volume":"129","author":[{"given":"Zafeirenia","family":"Vlakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8218-950X","authenticated-orcid":false,"given":"Anna","family":"Keramida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Kotsali-Peteinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-1293","authenticated-orcid":false,"given":"Alexandros","family":"Matsingos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Konstantinidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0509-5910","authenticated-orcid":false,"given":"Anastasios","family":"Bonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-6323","authenticated-orcid":false,"given":"Panagiota-Eleni","family":"Tsalouchidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2025.03.012_bib0001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0002","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.03.012_bib0003","article-title":"Drug-resistant idiopathic generalized epilepsy: a meta-analysis of prevalence and risk factors","volume":"146","author":"Jiang","year":"2023","journal-title":"Epilepsy Behav E&B"},{"key":"10.1016\/j.seizure.2025.03.012_bib0004","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1111\/epi.17410","article-title":"Drug resistance in idiopathic generalized epilepsies: evidence and concepts","volume":"63","author":"Gesche","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-024-00546-6","article-title":"Developmental and epileptic encephalopathies","volume":"10","author":"Scheffer","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.seizure.2025.03.012_bib0006","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/epi.14569","article-title":"Evolution and course of early life developmental encephalopathic epilepsies: focus on Lennox-Gastaut syndrome","volume":"59","author":"Berg","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0007","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2025.03.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109950","article-title":"Overview of clinical and physiologic aspects of status epilepticus in the developmental and epileptic encephalopathies","volume":"159","author":"Wirrell","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.03.012_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211070209","article-title":"Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy","volume":"14","author":"Singh","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.seizure.2025.03.012_bib0012","doi-asserted-by":"crossref","first-page":"E2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.03.012_bib0013","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013Drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.03.012_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2025.03.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200133","article-title":"Cenobamate in generalized epilepsy and combined generalized and focal epilepsy","volume":"13","author":"Agashe","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.seizure.2025.03.012_bib0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/jcm12010129","article-title":"Treatment with Cenobamate in adult patients with Lennox\u2013Gastaut Syndrome: a case series","volume":"12","author":"Falcicchio","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.seizure.2025.03.012_bib0017","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0018","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/epi.16752","article-title":"Epilepsy with myoclonic-atonic seizures (Doose syndrome): clarification of diagnosis and treatment options through a large retrospective multicenter cohort","volume":"62","author":"Nickels","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0019","unstructured":"PROSPERO International Prospective Register of Systematic Reviews. Centre for Reviews and Dissemination. University of York. https:\/\/www.crd.york.ac.uk\/prospero\/."},{"key":"10.1016\/j.seizure.2025.03.012_bib0020","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"The BMJ"},{"key":"10.1016\/j.seizure.2025.03.012_bib0021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.seizure.2025.03.012_bib0022","unstructured":"R Core Team. R: a language and environment for statistical computing 2024."},{"key":"10.1016\/j.seizure.2025.03.012_bib0023","first-page":"109","article-title":"Cenobamate: preliminary results of efficacy and safety in a real-life setting","volume":"29","author":"Falcicchio","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2025.03.012_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1209487","article-title":"Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction","volume":"14","author":"Friedo","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2025.03.012_bib0025","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0026","article-title":"Safety and effectiveness of cenobamate in down syndrome: a case report","author":"Corniello","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.seizure.2025.03.012_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2025.03.012_bib0028","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0029","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.012_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109888","article-title":"Survey of rehabilitation approaches and plans for individuals with dravet syndrome (RAPIDS) in Italy: current practices and strategies to progress","volume":"157","author":"Porto","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.03.012_bib0031","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/epi4.12413","article-title":"A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway","volume":"5","author":"Heger","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.03.012_bib0032","first-page":"98","article-title":"Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study","author":"Rosenfeld","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.03.012_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","article-title":"Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study","volume":"38","author":"Serrano-Castro","year":"2024","journal-title":"CNS Drugs"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:20:44Z","timestamp":1782973244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"alternative-id":["S1059131125000767"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.03.012","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}